Drug Profile

Research programme: cancer therapeutics - Apeiron-Therapeutics---Recursion Pharmaceuticals-(JV)

Alternative Names: CDK7 inhibitors - Apeiron-Therapeutics---Recursion Pharmaceuticals-(JV)

Latest Information Update: 29 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exscientia
Developer Recursion Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Cyclin-dependent kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
21 Jul 2021 Preclinical trials in Cancer in United Kingdom, China (unspecified route)
21 Jul 2021 Preclinical pharmacodynamics data in Cancer released by Apeiron-Therapeutics---Exscientia-(JV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com